Fatty Liver Stool Colour: What It Means

Fatty liver stool colour changes are a concern for many people living with or at risk of fatty liver disease. The liver plays a central role in producing bile, the digestive fluid responsible for giving stools their normal brown colour. In early fatty liver disease, stool colour is usually unaffected, but as the condition progresses to fibrosis or cirrhosis, or when complications arise, noticeable changes can occur. This article explains what different stool colours may indicate for liver health, which accompanying symptoms require urgent attention, and what lifestyle changes can help manage fatty liver disease effectively.

Can fatty liver disease change the colour of your stools?

Fatty liver disease can alter stool colour in advanced stages when bile flow is disrupted, but in early NAFLD stool colour is usually normal. Persistent pale or dark stools warrant GP assessment.

Fatty liver disease can affect stool colour, but this is more likely in advanced stages where liver function is significantly impaired rather than in early, uncomplicated disease. The liver produces bile, a digestive fluid that travels through the bile ducts into the small intestine and gives stools their characteristic brown colour.^[6][7] When fatty liver disease progresses to cirrhosis, bile flow can be disrupted, leading to noticeable changes in stool appearance. Pale or clay-coloured stools in someone with liver disease may also reflect a coexisting biliary problem, such as gallstones, a bile duct stricture or a biliary or pancreatic tumour, rather than fatty liver disease itself causing mechanical obstruction of the bile duct.

In early non-alcoholic fatty liver disease (NAFLD, also referred to in some clinical settings as metabolic dysfunction-associated steatotic liver disease, or MASLD), stool colour is usually unaffected. NICE guidance (NG49) continues to use the term NAFLD, and this remains the most widely used term in NHS clinical practice.^[1][2] The liver retains enough functional capacity to produce and secrete bile normally in early disease. It is only when significant scarring (fibrosis or cirrhosis) develops, or when a complication such as portal hypertension arises, that stool changes become clinically relevant.

In UK primary care, NAFLD is typically assessed using liver function tests alongside a non-invasive fibrosis risk score such as the FIB-4 index or the NAFLD Fibrosis Score.^[1][3] Where these suggest significant fibrosis, second-line tests such as the Enhanced Liver Fibrosis (ELF) score or transient elastography (FibroScan) may be arranged, with referral to hepatology if thresholds are met. This pathway is set out in NICE NG49.

It is worth noting that many factors unrelated to liver disease can alter stool colour, including diet, medications, iron supplements and gastrointestinal infections. A single episode of unusual stool colour is therefore not automatically a sign of liver disease. However, persistent or unexplained changes in stool colour, particularly pale or very dark stools, warrant medical assessment. If you notice ongoing changes, contact your GP for evaluation rather than assuming a dietary cause.

What do different stool colours mean for liver health?

Pale or clay-coloured stools indicate reduced bile reaching the intestine, while black tarry stools suggest upper gastrointestinal bleeding; both require prompt medical evaluation.

Pale, clay-coloured or white stools are the most clinically significant stool change associated with liver and bile duct problems, as they indicate that bile is not reaching the intestine in sufficient quantities. Bile contains a pigment called stercobilin, derived from the breakdown of bilirubin, which gives stools their normal brown colour.^[6][7] When bile flow is blocked or severely reduced, stools lose this pigmentation and appear pale, grey or chalky.

Dark or tarry black stools (known medically as melaena) can indicate bleeding in the upper gastrointestinal tract. In people with advanced liver disease and cirrhosis, this may result from ruptured oesophageal varices, which are enlarged veins caused by portal hypertension.^[12][13] Melaena is typically sticky, tarry and malodorous, and is a medical emergency requiring immediate assessment at an accident and emergency department. It is worth noting that iron supplements and bismuth-containing medicines can also darken stools considerably; however, if there is any doubt about whether dark stools represent melaena, treat it as an emergency.

Yellow or greasy stools may suggest fat malabsorption (steatorrhoea), which can occur when bile production or secretion is impaired. Classic features of steatorrhoea include pale, bulky, foul-smelling stools that may float and be difficult to flush, reflecting undigested fat passing through the bowel due to reduced bile availability. Bright red blood in or on stools is more commonly associated with lower gastrointestinal causes such as haemorrhoids, but should always be assessed by a GP, particularly in someone with known liver disease.

Green stools are usually caused by rapid intestinal transit or a diet high in leafy vegetables and are rarely a sign of liver disease. Context, persistence and accompanying symptoms are all important when interpreting stool colour changes.

Which symptoms alongside stool changes should worry you?

Pale stools combined with jaundice and dark urine indicate obstructive jaundice requiring same-day medical attention; black tarry stools or vomiting blood are emergencies requiring 999.

Pale stools combined with dark urine and yellowing of the skin or whites of the eyes (jaundice) together suggest a significant problem with bile flow and require prompt medical attention, ideally by contacting your GP the same day or calling NHS 111 for urgent advice. This combination of symptoms points to obstructive jaundice, which most commonly results from gallstones, bile duct strictures or pancreatic and biliary tract cancers. Painless obstructive jaundice in particular warrants urgent assessment, as it may indicate a pancreatic or biliary tumour; NICE guidance (NG12) sets out urgent suspected cancer referral pathways for this presentation.^[11] Primary liver cancer is a less typical cause of mechanical bile duct obstruction.

The following symptoms alongside stool changes should prompt you to seek medical advice without delay:

• Jaundice (yellow skin or eyes)

• Dark, tea-coloured urine

• Persistent abdominal pain, particularly in the upper right side

• Swelling of the abdomen (ascites), which may indicate fluid accumulation

• Unexplained weight loss or loss of appetite

• Extreme fatigue that is new or worsening

• Confusion or difficulty thinking clearly, which can indicate hepatic encephalopathy

Two additional emergency presentations are worth knowing. Jaundice combined with fever and right upper quadrant pain (sometimes called Charcot's triad) may indicate ascending cholangitis, a serious bile duct infection requiring same-day hospital assessment.^[10] In someone with known cirrhosis, fever alongside abdominal pain, worsening ascites or new confusion may suggest spontaneous bacterial peritonitis, which also requires urgent hospital review.^[8][9]

Black, tarry stools or vomiting blood are emergencies. Call 999 or go directly to accident and emergency if either of these occurs, as they may indicate life-threatening gastrointestinal bleeding.

For people already diagnosed with fatty liver disease, NICE guidance (NG49) recommends regular monitoring through your GP or specialist team, including non-invasive fibrosis assessment. Any new or worsening symptoms should be reported promptly rather than waiting for a routine appointment. Early identification of disease progression significantly improves outcomes.

What lifestyle changes can help improve fatty liver disease?

Weight loss of 5 to 10 per cent through a healthy diet and regular physical activity is the most effective intervention for fatty liver disease, supported by NICE guidance NG49.

Sustained weight loss through a combination of a healthy diet and regular physical activity is the most effective intervention for improving fatty liver disease in people who are overweight or living with obesity, according to NICE guidance (NG49). Even a modest reduction in body weight of 5 to 10 per cent has been shown to reduce liver fat and inflammation. A loss of greater than 10 per cent may lead to improvement in fibrosis in some individuals. These figures are supported by NICE NG49 and major hepatology society guidance including from the European Association for the Study of the Liver (EASL).

Dietary changes that are particularly beneficial include:

• Reducing intake of ultra-processed foods, refined carbohydrates and added sugars, including sugary drinks

• Limiting saturated fat from sources such as fatty meat, full-fat dairy and pastries

• Increasing fibre intake through vegetables, legumes, wholegrains and fruit

• Following a Mediterranean-style eating pattern, which has good evidence for liver health^[14][15]

• Avoiding alcohol entirely or reducing intake significantly, as alcohol accelerates liver damage even in NAFLD, per NICE NG49^[1][3]

Regular physical activity, including both aerobic exercise (such as brisk walking, cycling or swimming) and resistance training, independently reduces liver fat even without significant weight loss.^[21][22] The UK Chief Medical Officers' physical activity guidelines, reflected in NHS guidance, recommend at least 150 minutes of moderate-intensity activity per week for adults, alongside muscle-strengthening activity on two or more days per week.^[18][19]

For people who meet eligibility criteria, a GP or specialist may discuss whether pharmacological support for weight management is appropriate. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a clinician can assess whether any treatment is appropriate for an individual's circumstances.

Smoking cessation, managing type 2 diabetes and treating high blood pressure and raised cholesterol are also important components of a comprehensive approach to fatty liver disease, as these conditions accelerate disease progression.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
2. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49) – Recommendations for research.
3. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49) – Full guideline PDF.
4. Non-Alcoholic Fatty Liver Disease: Assessment and Management (NGC UK).
5. Non-alcoholic fatty liver disease (NAFLD).
6. Symptoms – Primary biliary cholangitis.
7. Valdoxan (agomelatine) – Product Information.
8. Cirrhosis in over 16s: assessment and management (NG50).
9. Spontaneous bacterial peritonitis in non-cirrhotic portal hypertension secondary to primary myelofibrosis: A rare case report.
10. Obstruction of the Biliary and Urinary System.
11. Suspected cancer: recognition and referral (NG12).
12. Gastric varices: a contemporary review of vascular anatomy and therapeutic strategies.
13. Massive Esophagogastric Variceal Bleeding from Chronic Portal Vein Thrombosis in a Non-Cirrhotic Young Man.
14. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease.
15. Impact of weight loss and reduction of ultra-processed foods on liver fat content in MASLD: A randomized controlled trial.
16. A culturally adapted online Mediterranean diet intervention for metabolic dysfunction-associated steatotic liver disease (TIMA): study protocol for a randomized controlled trial.
17. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomized controlled trials.
18. Physical activity guidelines: UK Chief Medical Officers' report.
19. UK Chief Medical Officers' physical activity guidelines.
20. Physical activity guidelines for adults aged 19 to 64.
21. Exercise Training Is Associated With Treatment Response in Liver Fat Content by MRI Independent of Clinically Significant Body Weight Loss in NAFLD: A Systematic Review and Meta-Analysis.
22. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
23. Weight Loss as a Determinant of Histological Improvement in MASLD in People With Obesity: A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.
24. Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: A meta-analysis of randomized controlled trials.

Frequently Asked Questions